Skip to main content

13-12-2010 | Cardiology | Article

Nebivolol reduces ischemic events in patients with ischemic HF


Free abstract

MedWire News: Study results indicate that elderly patients with ischemic heart failure (HF) who are treated with nebivolol have a reduced 2-year risk for cardiac ischemic events, irrespective of gender and heart failure severity.

"It is conceivable that this [anti-ischemic] characteristic is also shared by other beta-blockers, and that it has simply gone undetected because previous studies did not systematically look for this type effect," the study authors suggest.

Giuseppe Ambrosio (University of Perugia School of Medicine, Italy) and colleagues assessed 2-year cardiac ischemic event rates (defined as death or hospitalization for myocardial infarction, unstable angina, or sudden death) among 2128 patients aged 70 years or older.

All patients had ischemic HF secondary to coronary artery disease (CAD), and were randomly allocated to receive nebivolol (n=735) or placebo (n=717) for 2 years.

Over the follow-up period, fewer cardiac ischemic events occurred among patients taking nebivolol than those taking placebo, at 10.7% and 15.9%, respectively.

This, say Ambrosio and colleagues, is equivalent to a 32% reduction in cardiac ischemic event risk among patients taking nebivolol compared with placebo (p=0.008), even after adjustment for gender, age, and left ventricular ejection fraction.

When the researchers analyzed a subgroup of 676 patients with HF secondary to a nonischemic cause, they observed a similar trend to that seen in the main study. Specifically, a nonsignificant 14% reduction in cardiac ischemic event risk in patients taking nebivolol compared with placebo.

Ambrosio et al conclude: "Our findings support the hypothesis that beta-blockers may also benefit HF patients with previous coronary disease through anti-ischemic mechanisms, and provide further evidence of the importance of nebivolol in elderly patients with HF."

MedWire ( is an independent clinical news service provided by Current Medicine Group, a trading division of Springer Healthcare Limited. © Springer Healthcare Ltd; 2010

By Lauretta Ihonor

Related topics